Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRM-151 in Idiopathic Pulmonary Fibrosis
NCT02550873Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2015
- Primary completion
- May 2017
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 7
01
Overview
A Phase 2 trial of zinpentraxin alfa in idiopathic pulmonary fibrosis (IPF), sponsored by Roche. Started Sep 2015; status: completed.
02
Drugs
zinpentraxin alfa
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02550873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02550873.